their assistance in the conduct, reporting, and quality control ofthe studies; the DURATION-5 study site investigators (FredWhitehouse, Jesse Wallace, Ronald Graf, Cristian Breton, LindaGaudiani, Elmer Stout, Eric Klein, Kenneth Hershon, RichardBeasley, Lusiana Loman, Sanford Plevin, Patricia Buchanan,Ronald Stegemoller, Dean Keraiakes, Kenneth Sall, LeonardChuck, Peter Weissman, Thomas Moretto, Jolene Berg, ErnestoFuentes, Matthew Davis, Raymond Fink, David Kayne, DarioAltamirano, Bruce Berwald, Louise Tabor, Richard Carlson,Lyle Myers, Jeffrey Geohas, Sheila Rodstein, Wayne Harper,Carol Wysham, Anna Chang, Nabil Andawis, Nashwa Gabra,Bruce Rankin, Bruce Barker, Eli Roth, Daniel Weiss, Jaime San-doval, Douglas Denham, John Pullman, and Thomas Blevins)and their staffs for conducting the study; the study patients fortheir participation; and Alkermes, Inc. for the development of thelong-acting release formulation of exenatide. Address all correspondence and requests for reprints to: